IP Library Granted Patent US 39,150
Granted Patent E1
US 39,150 · App. 09/823,775 · Granted Jun 27, 2006

Composition for creating vascular occlusions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 39,150
App. No.
09/823,775
Granted
Jun 27, 2006
Kind
E1
Abstract

A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.

Claims (9)

1. A composition for creating therapeutic vascular occlusions in an animal comprising a mixture of:

(a) Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid; and

(b) Part 2 comprising gold metal powder, ethyl myristate and a sterilized a large chain fatty acid ester in liquid form and a stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution .

2. The composition of claim 1 wherein Part 1 comprises about 100 PPM hydroquinone, 100 PPM p-methoxyphenol, 250 PPM phosphoric acid and the remainder 2-hexyl cyanoacrylate.

3. The composition of claim 2 wherein Part 2 comprises about 65 percent by weight gold, about 30 percent by weight ethyl myristate and the remainder said sterilized stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solut ion .

4. The composition of claim 1 wherein Part 2 includes sulfur dioxide as a stabilizer.

5. A method for creating therapeutic vascular occlusions in an animal needing therapeutic vascular occlusion comprising the steps of:

(a) Mixing together Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid with Part 2 comprising gold metal powder, ethyl myristate and a sterilized a large chain fatty acid ester in liquid form, and a stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution ; and

(b) injecting administrating the mixture into a vascular site needing occlusion with the gold metal powder suspended in the mixture .

Assignments (10)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 7, 2020
From: STRYKER EUROPEAN HOLDINGS I, LLC
To: STRYKER EUROPEAN HOLDINGS III, LLC
Reel/Frame 052861/0001 →
CHANGE OF NAME Recorded Jun 7, 2020
From: STRYKER EUROPEAN HOLDINGS III, LLC
To: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
Reel/Frame 052860/0716 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL # 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0034. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT. Recorded Mar 8, 2016
From: STRYKER NV OPERATIONS LIMITED
To: STRYKER MEDTECH LIMITED
Reel/Frame 038039/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTED SERIAL NOS. 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0241. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE 9/29/2014. Recorded Mar 8, 2016
From: STRYKER MEDTECH LIMITED
To: STRYKER EUROPEAN HOLDINGS I, LLC
Reel/Frame 038043/0011 →
NUNC PRO TUNC ASSIGNMENT Recorded Nov 23, 2015
From: STRYKER NV OPERATIONS LIMITED
To: STRYKER MEDTECH LIMITED
Reel/Frame 037153/0034 →
NUNC PRO TUNC ASSIGNMENT Recorded Nov 23, 2015
From: STRYKER MEDTECH LIMITED
To: STRYKER EUROPEAN HOLDINGS I, LLC
Reel/Frame 037153/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2011
From: BOSTON SCIENTIFIC CORPORATION
To: STRYKER CORPORATION; STRYKER NV OPERATIONS LIMITED
Reel/Frame 025959/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2005
From: PROVASIS THERAPEUTICS, INC.
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 016274/0547 →
CHANGE OF NAME Recorded Jan 21, 2005
From: PROHOLD TECHNOLOGIES, INC.; PROHOLD MEDICAL CORPORATION
To: PROVASIS THERAPEUTICS, INC.
Reel/Frame 015583/0694 →
JUDGMENT LIEN Recorded Dec 30, 2004
From: PROVASIS THERAPEUTICS, INC.
To: HUB PROPERTIES TRUST
Reel/Frame 015503/0037 →